Browsing Tag
IntraBio
2 posts
IntraBio files first-ever FDA application for an Ataxia-Telangiectasia drug with AQNEURSA sNDA submission
IntraBio filed the first-ever FDA application for Ataxia-Telangiectasia via an AQNEURSA sNDA. Read what the Phase III data means for patients and the rare disease market.
IntraBio’s AQNEURSA earns positive CHMP opinion, bringing Niemann-Pick disease type C therapy closer to EU approval
IntraBio’s AQNEURSA earns positive CHMP opinion for Niemann-Pick disease type C, moving closer to EU approval after strong Phase III data and U.S. FDA nod.